Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

by B2i | May 26, 2023 | Press Releases

ROCKVILLE, Md., May 26, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a...

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

by B2i | May 17, 2023 | Press Releases

ROCKVILLE, Md., May 17, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) (the...

Shuttle Pharmaceuticals Enters Research Agreement for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

by B2i | Mar 22, 2023 | Press Releases

ROCKVILLE, Md., March 22, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

by B2i | Mar 15, 2023 | Press Releases

ROCKVILLE, Md., March 15, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a...

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

by B2i | Mar 9, 2023 | Press Releases

ROCKVILLE, Md., March 9, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it...